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Abstract
Background:  Autosomal dominant polycystic kidney disease (ADPKD) is a genetically
heterogeneous disorder caused by mutations in at least two different loci. Prior to  performing
mutation screening, if DNA samples of  sufficient number of family members are available, it  is
worthwhile to assign the gene involved in disease  progression by the genetic linkage analysis.
Methods: We collected samples from 36 Slovene ADPKD families and performed linkage analysis
in 16 of them. Linkage was assessed by the use of microsatellite polymorphic markers, four in the
case of PKD1 (KG8, AC2.5, CW3 and CW2) and five for PKD2 (D4S1534, D4S2929, D4S1542,
D4S1563 and D4S423). Partial PKD1 mutation screening was undertaken by analysing exons 23 and
31–46 and PKD2 .
Results: Lod scores indicated linkage to PKD1 in six families and to PKD2 in two families. One
family was linked to none and in seven families linkage to both genes was possible. Partial PKD1
mutation screening was performed in 33 patients (including 20 patients from the families where
linkage analysis could not be performed). We analysed PKD2 in 2 patients where lod scores
indicated linkage to PKD2 and in 7 families where linkage to both genes was possible. We detected
six mutations and eight polymorphisms in PKD1 and one mutation and three polymorphisms in
PKD2.
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Conclusion:  In our study group of ADPKD patients we detected seven mutations: three
frameshift, one missense, two nonsense and one putative splicing mutation. Three have been
described previously and 4 are novel. Three newly described framesfift mutations in PKD1 seem to
be associated with more severe clinical course of ADPKD. Previously described nonsense mutation
in PKD2 seems to be associated with cysts in liver and milder clinical course.
Background
Autosomal dominant polycystic kidney disease (ADPKD;
MIM:173900) is a common genetic disease of the kidney,
with a population frequency of ~0.1% [1]. It is character-
ized by progressive renal cystic disease, typically leading
to end-stage renal disease (ESRD) in late middle age.
ADPKD accounts for approximately 5% of ESRD in west-
ern countries. The rate of progression towards kidney fail-
ure is variable and whilst end-stage renal failure (ESRF)
most commonly occurs in the fifth decade [2] it can
present as early as in utero whereas some individuals may
never progress to renal failure [3-5]. The disorder is genet-
icaly heterogeneous with two genes implemented; PKD1
on 16p13.3 (MIM:601313) and PKD2  on 4q21-23
(MIM:173910) [6,7]. Cases of families unlinked to either
of the loci have also been described [8]. PKD1 accounts
for approximately 85% of cases and is associated with a
more severe disease course (average age at onset of ESRD
of 53 compared to 69 years for PKD2) [9]. Renal cysts are
likely to develop only after a second-hit or somatic muta-
tion, which inactivates the inherited normal allele of the
same locus, or occasionally an allele of another counter-
part locus, giving rise to a transheterozygous event [10].
Polycystin-1, the protein encoded by PKD1, is predicted to
be a large transmembrane glycoprotein [11,12]. PKD2
codes for polycystin-2 which functions as a non-selective
cation channel that can conduct calcium ions [7,13]. It
has been shown that the two proteins interact with each
other via their C-terminal regions and possibly function as
flow-sensitive mechanosensors in the primary cilium of
the renal epithelium cells [14]. A failure of fluid-flow sen-
sation of the cells may disturb tissue morphogenesis and
trigger abnormal cell proliferation and cyst formation.
Although presymptomatic diagnosis of ADPKD is possi-
ble by various imaging methods and is relatively reliable
in adult patients, genetic diagnosis is important for pre-
symptomatic diagnosis in younger individuals and in
cases with no family history of the disease. Mutation
screening in ADPKD is a cumbersome and expensive proc-
ess as PKD1 is large and most of it is reiterated in the form
of homologues genes (HG) at least six times on the same
chromosome [15]. The presence of HG complicates muta-
tion screening in PKD1  as classic PCR amplifies both
PKD1  as well as HG sequences. Several groups have
already successfully screened most of the coding region of
PKD1 [15-22]. From these studies it is apparent that muta-
tions are dispersed across the entire PKD1  and  PKD2
genes with no clustering in mutation 'hot spots'. The
majority of them are found to be private. It is therefore
worthwhile to first assign the gene involved in a particular
ADPKD family before proceeding with mutation screen-
ing. Nevertheless less than half of our ADPKD families fit-
ted to the criteria for performing linkage analysis and only
in those families could we preselect the ones suitable for
PKD1 or PKD2 screening. Due to a limited budget we have
screened only a part of the PKD1 gene and the entire PKD2
gene.
Methods
Patients and families
We collected samples of 36 Slovene ADPKD families.
Linkage studies were performed in 16 families (compris-
ing 48 patients and 41 healthy family members) where
samples of at least three affected members or two affected
and two unaffected members were available. Ultrasound
examination and confirmed history of ADPKD in the fam-
ilies was required to enter the study. Diagnosis of ADPKD
was based on ultrasonographic criteria described by
Ravine at al., 1994 [23]. The study was approved by the
Slovenian Medical Ethics Committee and research was
conducted in accordance with the Helsinki Declaration.
Linkage analysis
Genomic DNA was extracted from white blood cells by
the standard salting out procedure [24]. We developed
three fluorescent multiplex PCR reactions for simultane-
ous amplification of 9 polymorphic PKD1  and  PKD2
associated microsatellites: D16S3252 (KG8), D16S665
(SM6), D16S291 (AC2.5), D16S664 (CW3), D16S663
(CW2), D4S1534, D4S2929, D4S1563 and D4S423. We
determined amplified product lengths using capillary
electrophoresis. Details about primer pairs, labelling,
cycling conditions and capillary electrophoresis proce-
dures have been described previously [25].
In addition, we also analysed two intragenic RFLPs,
p.A4058V and p.A4091A as described previously [26].
Prior to performing linkage analysis we characterised the
number of alleles, their sizes, frequencies and heterozy-
gosity content for each microsatellite in a group of 27–42
unrelated individuals. Then we calculated two-point Lod
scores using MLINK and ILINK options of LINKAGE 5.1BMC Medical Genetics 2006, 7:6 http://www.biomedcentral.com/1471-2350/7/6
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[27]. In order to be able to calculate Lod scores in batches
for all families and pairs of loci we added two small sub-
programs to the LINKAGE 5.1 pedin.bat accordingly.
A gene frequency of 0.001 was assumed for PKD1 and
0.0001 for PKD2. For PKD1, three liability classes were
assumed, corresponding to gene penetrances of 0.64,
0.92, and 0.99 for age groups 0–10, 10–30 and over 30
years respectively [28,29]. For PKD2, the liability classes
assumed were 0.50, 0.85, and 0.95 for age groups 0–20,
20–30 and over 30 years respectively [30]. Linkage calcu-
lations were carried out under an assumption of no differ-
ence between the female and male recombination rate
and the absence of genetic interference.
Mutation screening
We screened PKD1 exons 23 and 31–46 for mutations
using direct sequencing. Primer sequences and PCR con-
ditions are available on request. Prior to sequencing, we
purified PCR products through QIAquick columns (Qia-
gen QIAquick PCR Purification Kit). We analysed
sequences on a Perkin Elmer Thermocycler 9600 using
Ready Big Dye Terminator Cycle Sequencing Kit according
to the protocol of the producer (Applied Biosystems).
Primer sequences and PCR conditions for PKD2  exon
amplification are available on request. We performed het-
eroduplex analysis (HA) using Hydrolink Mutation
Detection Enhancement (MDE, BMI) gel solution. Com-
plete PCR products (50 µl) were mixed with 0.5 µl 0.5 M
EDTA, denatured at 95°C for 5 min and finally cooled at
37°C for at least 1 hour. We analysed 5:1 ratio of sample
and loading dye by electrophoresis through 25 cm-1 ×
MDE gel with 15% urea at 250 V for 16–24 h. Then we
stained gels with ethidium bromide and photographed
them under UV light. DNA samples exhibiting shifted
bands we amplified and sequenced in both directions
using ABI Prism™ 310 Genetic Analyzer (Applied Biosys-
tems) according to the manufacturer's instructions. The
detected changes we tested for segregation in each family
by either HA or direct sequencing.
Data analysis
Putative missense changes in PKD1 we further analysed
for their site conservation in mouse (GenBank:U70209),
rat (GenBank:AF277452), cat (GenBank:AF483210) and
puffer fish (GenBank:AF013614) cDNA sequences, using
BLAST [31]. The effect of these mutations on the predicted
secondary structure of the protein was analysed by PHD-
sec http://cubic.bioc.columbia.edu/pp/[32,33].
Results
Linkage analysis
We calculated linkage to PKD1 by only four out of the five
microsatellite markers used (/PKD1/-KG8-AC2.5-CW3-
Pedigree of the family 42 and possible haplotypes for the  PKD1 (top) and PKD2 (bottom) associated polymorphic  markers Figure 1
Pedigree of the family 42 and possible haplotypes for 
the PKD1 (top) and PKD2 (bottom) associated poly-
morphic markers. Black boxes or circles indicate the 
affected and empty ones the healthy family members. Num-
bers indicate lengths of PCR products (in bp) for different 
alleles of the chosen microsatellites. Names of the PKD1 and 
PKD2 associated polymorphic markers are located on the left 
of the haplotype bars. Changes in colour of the haplotype 
bars indicate possible recombination events. Lod scores and 
corresponding maximal recombination fractions (Zmax, Θmax) 
were calculated for KG8 (-0.86919, 0.035), AC2.5 (-
1.738298, 0.035), CW3 (-0.869292, 0.035) and CW2 (-
1.738492, 0.035) polymorphic markers. Negative values Zmax 
indicate exclusion of linkage to PKD1. KG8 lies within 3'-part 
of the PKD1 gene and the other markers are located proxi-
mally to the PKD1 on 16p13.3.BMC Medical Genetics 2006, 7:6 http://www.biomedcentral.com/1471-2350/7/6
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CW2). We excluded SM6 from Lod score calculations as
the correct determination of alleles was impossible due to
stutter products and appearance of new alleles during
pedigree analysis (also reported by Peral et al., 1994 [29]).
In addition, we used two intragenic RFLPs, p.A4058V and
p.A4091A, which helped in deducing allele segregation in
some of the families that were not very informative for
KG8. Subsequently we did not include them in calcula-
tion of Lod scores due to their low informativity. Linkage
to  PKD2  we analysed using five microsatellite markers
(D4S1534-D4S2929-D4S1542-/PKD2/-D4S1563-
D4S423).
In six families Lod scores and segregation of alleles indi-
cated probable linkage to PKD1 (pedigrees 05, 11, 21, 24,
25 and 36) and in two families to PKD2 (pedigrees 10 and
Table 1: Clinical data of the patients from the family 42
Patient 171/fam 42 172/fam 42 174/fam 42 175/fam42 176/fam42
G e n d e r MMF MM
Age (years) 66 38 32 16 14
Age of onset (years) 66 35 32 14 7
Blood pressure H H; on therapy N N N
Serum creatinin 
(µmol/l)
not measured not measured 80 105 75
Ultrasound of liver not done numerous cysts normal normal normal
Ultrasound of kidneys enlarged kidneys, large 
cysts
enlarged kidneys, large 
cysts, calcinations
cysts several small cysts several small cysts
Dialysis (age at start in 
years)
no no; first signs of 
insufficiency
no no no
Additional symptoms severe arterial 
hypertension
headaches
M or F designate male or female patients. Normal values for blood pressure are less then 120/80 mm Hg, (in the table designated as N) values from 
120/80 mm Hg up to 139/89 mm Hg indicate prehypertension (P) and values above 140/90 indicate hypertension (H). Normal values for serum 
creatinin are 70–115 µmoles/l for men and 52–97 µmoles/l for women.
Table 2: Sequence changes identified in PKD1 and PKD2. PKD1 cDNA reference sequence is Entrez:NM_000296 (RefSeq database) 
and PKD2 cDNA reference sequence is Entrez:NM_000297 (RefSeq database).
Sequence change Location Amino Acid Change Predicted effect on 
protein
Found in family Reference
c.8509C>T exon 23 (PKD1) no change silent polymorphism 02 present study
c.8522G>A exon 23 (PKD1) p.E2771K missense mutation 25 [18]
c.8675G>A exon 23 (PKD1) p.V2822M probably 
polymorphism
09 present study
c.11477+128C>T intron 39 (PKD1) intronic polymorphism 19, 25, 39, 43, 46 present study
c.11693_11697dup exon 41 (PKD1) frameshift premature stop codon 41 present study
c.11745+3_5dup intron 41 (PKD1) intronic possibly influences 
splicing
38 [34]
c.11820_11845del exon 42 (PKD1) frameshift premature stop codon 20 present study
c.12124C>T exon 43 (PKD1) no change silent polymorphism 12, 27 present study
c.12341A>G exon 44 (PKD1) p.I4044V polymorphism 11, 19, 21, 25, 27, 39, 
43, 46, 49
[35]
c.12346+22del intron 44 (PKD1) intronic polymorphism 12, 27 [36]
c.12375G>A exon 45 (PKD1) p.W4055X nonsense mutation 50 present study
c.12772dup exon 46 (PKD1) frameshift premature stop codon 11 present study
c.12838T>C exon 46 (PKD1) no change silent polymorphism 11, 19, 21, 25, 27, 39, 
43, 46, 49
[37]
c.12973C>T exon 46 (PKD1) no change silent polymorphism 20 [38]
c.83G>C exon 1 (PKD2) p.R28P polymorphism 31 [39]
c.362C>G exon 1 (PKD2) p.G121A probably 
polymorphism
31 present study
c.844-22 G>A intron 3 (PKD2) no change polymorphism 31 [40]
c.916C>T exon 4 (PKD2) p.R306X nonsense mutation 10 [40]B
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Table 3: Clinical data of the patients from families 10, 11, 20, 25, 38 and 41 in which we identified presumably pathogenic changes
Patient Mutation/gene Gender Age (years) Age of onset 
(years)
Blood 
pressure
Serum 
creatinin 
(µmol/l)
Ultrasound of 
liver
Ultrasound of kidneys Dialysis (age at 
start in years)
Additional symptoms
33 
fam 10
c.916C>T p.R306X/PKD2 M 51 42 H 147 cysts in the left 
lobe and 
gallbladder
enlarged kidneys, large 
cysts, calcinations
no cardiac hypertrophy, 
malfunction of mitral 
valve
35 
fam 10
c.916C>T p.R306X/PKD2 F 23 14 N 62 lesion, arterial 
angioma
small cysts no focal nodular 
hyperplasia in liver
36 
fam 10
c.916C>T p.R306X/PKD2 F 18 9 N 53 normal small cysts no
37 
fam 11
c.12772dup/PKD1 M 58+ 34 H 1418 cysts, cirrhosis enlarged kidneys, 
numerous cysts
yes (46) kidney stone, 
obstructive icterus
40 
fam 11
c.12772dup/PKD1 F 23 11 N 82 normal small cysts no
77 
fam 20
c.11820_ 11845del/PKD1 F 56 46 P 450 cysts numerous cysts yes (48) idiopathic dilated 
cardiomyopathy
161 
fam 20
c.11820_11845del/PKD1 M 47 40 H 399 normal numerous cysts yes (44) persistent hepatitis B
89 
fam 25
c.8522G>A p.E2771K/PKD1 M 65 38 N 200 enlarged numerous cysts no; first signs 
of insufficiency
90 
fam 25
c.8522G>A p.E2771K/PKD1 F 42 28 N normal enlarged numerous cysts no
91 
fam 25
c.8522G>A p.E2771K/PKD1 F 61 40 N 700–800 enlarged with 
portal 
hypertension
numerous cysts yes (43) headaches
92 
fam 25
c.8522G>A p.E2771K/PKD1 M 40 32 N normal enlarged numerous cysts no
166 
fam 38
c.11745+3_5 dup/PKD1 F2 0 9 P n o t  
measured
normal enlarged kidneys, 
numerous small cysts
no endometriosis
148 
fam 41
c.11693_11697dup/PKD1 F 44 21 P 458 normal enlarged kidneys, cysts yes (44) gallstones
M or F designate male or female patients. Normal values for blood pressure are less then 120/80 mm Hg, (in the table designated as N) values from 120/80 mm Hg up to 139/89 mm Hg indicate 
prehypertension (P) and values above 140/90 indicate hypertension (H). Normal values for serum creatinin are 70–115 µmoles/l for men and 52–97 µmoles/l for women. Cross (+) designates 
death of the patient at the age of 58 years. For relation of the patients in the families 10, 11 and 25 see Figure 2 [see Figure 2]. Patients 77 and 161 from the family 20 are sister and brother. 
Clinical data for the patient 198 from the family 50 were not complete therefore we did not include them in the Table 3.BMC Medical Genetics 2006, 7:6 http://www.biomedcentral.com/1471-2350/7/6
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31). Linkage to both genes was possible in seven mostly
small families, where the co-segregation is likely to be due
to chance (pedigrees 02, 12, 14, 18, 27, 47 and 49). In one
of the 16 families analysed (pedigree 42), Lod scores were
mostly negative and linkage to neither of the two PKD loci
could be assumed. [see Figure 1] From segregation of alle-
les we concluded exclusion of linkage to both PKD loci in
this pedigree. Table 1 summarises clinical data for the
patients of the family 42. All families indicating linkage to
PKD1 to PKD2 or to either PKD1 or PKD2 were selected
for further mutation screening.
Mutation screening
Altogether 33 patients were included in the PKD1 muta-
tion screening. We selected one patient from each family
where calculated Lod scores did not indicate exclusion of
linkage to PKD1  (6 families with indicated linkage to
PKD1 and 7 families where linkage to both genes was pos-
sible) and 20 patients from families where linkage analy-
sis was not possible due to lack of family member
samples. We screened the PKD2 gene for mutations on 9
patients from families where linkage to the PKD2 gene
could not be excluded (2 families with linkage to PKD2
and 7 families where linkage to both genes was possible).
We identified seven likely ADPKD causing changes and
eleven polymorphisms in both genes. They are summa-
rised in Table 2. Then we checked for segregation of the
putative mutation with the ADPKD status, where DNA
samples of other family members were available. Table 3
summarises clinical data of the patients from the families
where pathogenic mutation was detected.
We found 3 changes in exon 23 of PKD1. The first change
is a silent polymorphism c.8509C>T that was detected in
family 02. The second change p.E2771K c.8522G>A is a
missense mutation already identified in 4 British families
[18]. The mutation changes a glutamate residue to a lysine
causing a net charge change of the predicted protein.
Using the PHDsec computer prediction analysis tool
[32,33] we predicted the change to affect the secondary
structure of up to 40 amino acid residues upstream. Segre-
gation with the disease was confirmed in the family. Table
3 summarises the clinical data of the four patients and Fig-
ure 2. shows a pedigree of the family 25 [see Figure 2]. All
four affected relatives have enlarged livers whilst blood
pressure remains within normal values.
The third change in exon 23 (PKD1) we detected is the
substitution from valine to methionine c.8675G>A
p.V2822M. We could not analyse for segregation because
no additional samples from other family members were
available. The valine residue is only conserved in the
cDNA sequences of the species cat, mouse and rat, but not
puffer fish. Our secondary structure analysis with PHDsec
[32,33] shows no drastic effect on the protein structure of
this helical domain.
In patient 148 of family 41 we found the duplication of
five base pairs in exon 41 (PKD1) c.11693_11697dup.
The predicted consequence of this duplication is most
probably termination of protein synthesis 116 amino acid
residues after glutamate 3828. Patient 148 has gallstones
and she started dialysis treatment at the age of 44 (rapid
progressor). Patient's daughter has enlarged kidneys with
multiple cysts at the age of 23 and she suffers from hyper-
tension and proteinuria. Blood sample of the patient's
daughter was not avaliable therefore we could not con-
firm segregation of the mutation in the family.
In family 38 we found the duplication of 3 base pairs in
intron 41 (PKD1) c.11745+3_5dup. The mutation was
described previously in a French patient under different
name 11745+2ins3 [34]. We adapted the name of the
mutation to the updated recommendation of the Human
Genome Variation Society HGVS (May, 2005). The muta-
tion possibly influences splicing of intron 41. We could
not analyse segregation due to lack of samples from the
family 38.
In two siblings (patients 77 and 161) from family 20 we
identified the deletion of 26 base pairs in exon 42 (PKD1)
c.11820_11845del. The mutation most probably results
in protein termination after 80 amino acid residues. Both
patients have already rather early started with dialysis
treatment: patient 77 at the age of 48 and patient 161 at
the age of 44. In patient 77 cysts in the liver and idiopathic
dilated cardiomyopathy were detected, while sibling 161
has persistent hepatitis B.
Previously described polymorphism in exon 44 (PKD1)
c.12341A>G p.I4044V [35] we found in nine apparently
unrelated pedigrees in the present study (families 11, 19,
21, 25, 27, 39, 43, 46, 49). In all these families polymor-
phism c.12341A>G p.I4044V co-segregated with another
also previously described silent polymorphism in exon 46
(PKD1) c.12838T>C [37].
In two apparently unrelated pedigrees (families 12 and
27) we found previously described intronic deletion in
intron 44 (PKD1) c.12346+22del [36]. In both families
the change does not segregate with the disease neverthe-
less it co-segregates with a silent polymorphism in exon
43 (PKD1) c.12124C>T.
In patient 198 (family 50) we found nonsense mutation
in exon 45 (PKD1 c.12375G>A p.W4055X. We are lacking
clinical data for the patient 198 nevertheless ultrasound
was performed for the patient's daughter. She has small
cysts in the kidneys that were detected at the age of 5 years.BMC Medical Genetics 2006, 7:6 http://www.biomedcentral.com/1471-2350/7/6
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Mother of the patient 198 has a transplanted kidney.
Blood samples of the two relatives were not available
therefore we could not confirm segregation of the muta-
tion in the family.
In family 11 [see Figure 2] we found the 1 base pair dupli-
cation in exon 46 of PKD1 c.12772dup. The mutation
most probably results in premature protein termination
after 20 amino acid residues. The duplication segregates
with the disease in the family 11. Patient 37 died at the age
of 58 years. He was operated on kidney stones and suf-
fered from liver cirrhosis as well as obstructive icterus. His
daughter (23 years) has small cysts in kidneys that were
detected at the age of 11.
In PKD2 gene we found four changes. In family 10 [see
Figure 2] we detected a nonsense mutation in exon 4
(PKD2) c.916 C>T p.R306X. The mutation was already
described in three Bulgarian families [40] and in two
Czech families with a mild clinical course of the disease
[41,42]. We confirmed segregation of the mutation with
the disease in the family 10. Patient 35 (age 51 years) lives
without dialysis treatment. He has enlarged kidneys con-
taining numerous large cysts. He suffers from cardiac
hypertrophy as well as from a malfunction of the mitral
valve. Focal nodular hyperplasia was detected in the liver
of his older daughter (patient 35).
In family 31 we detected three changes in the PKD2 gene.
In exon 1 (PKD2) we found the sequence change c.362
C>G p.G121A. This variation substitutes glycine for
alanine at the N-terminal region of polycystin 2. The
sequence change however does not segregate with the dis-
ease in the family 31. In the same family we also observed
the presence of two already described polymorphisms
c.83G>C, p.R28P in exon 1 and c.844-22 G>A in intron 3
[39,40].
Discussion
As both genes associated with ADPKD are large and muta-
tion screening is time consuming and costly, it is prudent
to assess linkage to either PKD1 or PKD2 prior to perform-
ing mutation analysis in ADPKD families. Of the 16 fam-
ilies included in linkage analysis, Lod scores and
segregation of alleles indicated probable linkage to PKD1
in six families (four two-generation families; and in two
three-generation families; pedigrees 05, 11, 21, 24, 25 and
36) and linkage to PKD2 was indicated in two families
(two two-generation families; pedigrees 10 and 31). Link-
age to both genes was possible in seven mostly small fam-
ilies, where co-segregation is likely to be due to chance
(pedigrees 02, 12, 14, 18, 27, 47 and 49). For one out of
the 16 families analysed (pedigree 42), Lod scores were
mostly negative and linkage to neither of the two PKD loci
could be assumed.
We consequently performed mutation screening in either
PKD1 or PKD2 in patients from families with indicative
linkage to either one or the other gene and in patients
from families where linkage to both genes was possible. In
addition we included patients from families where we
could not perform linkage studies due to a lack of samples
from family members. In total we screened 33 patients for
PKD1 mutations and 9 patients for PKD2 mutations.
Detection of mutations in the duplicated part of PKD1 has
been hindered by the high (>95%) sequence identity with
homologous genes, raising concerns about PCR primer
specificity and hence reliability of the analysis [43]. We
have focused on a limited area of the gene. In the present
study we screened the unduplicated region of PKD1
(exons 33–46) as well as exons 31–32 and exon 23 of the
Pedigrees of the families 10 and 25 with possible haplotypes  for the PKD1 associated polymorphic markers and pedigree  of family 11 with possible haplotypes for the PKD2 associated  polymorphic markers Figure 2
Pedigrees of the families 10 and 25 with possible hap-
lotypes for the PKD1 associated polymorphic mark-
ers and pedigree of family 11 with possible 
haplotypes for the PKD2 associated polymorphic 
markers. Black boxes or circles indicate the affected and 
empty ones the healthy family members. Crossed over boxes 
or circles designate deceased family members. Numbers indi-
cate lengths of PCR products (in bp) for different alleles of 
the chosen microsatellites. Names of the PKD1 and PKD2 
associated polymorphic markers are located on the left of 
the haplotype bars.BMC Medical Genetics 2006, 7:6 http://www.biomedcentral.com/1471-2350/7/6
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duplicated part. Exon 23 was analysed due to its' proxim-
ity to the IVS21 polypyrimidine tract, where clustering of
mutations has been proposed [44] due to formation of
putative triplex DNA structures [45,46]. Although no
apparent mutation 'hot spots' were found in PKD1, the
region around the polypyrimidine tract shows a higher
frequency of changes compared to other parts of the gene
[18].
Six mutations and eight polymorphisms were detected in
PKD1 and one mutation and three polymorphisms were
detected in PKD2. Three mutations were described previ-
ously; p.E2771K c.8522G>A (PKD1) in four British fami-
lies [18], c.11745+3_5dup (PKD1) in a French patient
[34] and p.R306X c.916C>T (PKD2) in three Bulgarian
[40] and two Czech families [41,42]. Four out of 7 muta-
tions are novel and probably private. All four of them
(c.11693_11697dup, c.11820_11845del, c.12375G>A
p.W4055X and c.12772dup in PKD1) most probably
result in premature protein termination.
As there is no functional assay for ADPKD and analysing
PKD1 in a sufficient number of control chromosomes is
costly, the distinction between disease causing mutations
and neutral variants has to rely on family segregation
studies. Segregation in family we confirmed for four out of
seven identified mutations where samples at least two
patients from the family were available. From the other
three, one mutation was described previously
(c.11745+3_5dup) [34], and from the other two
c.11693_11697dup is a frameshift and c.12375G>A
p.W4055X is a nonsense mutation.
On the basis of collected clinical data of the patients
which is summarised in Table 3. we tried to assess the
influence of the identified mutations on progression of
the disease. Three newly described framesfift mutations in
PKD1  c.12772dup, c.11820_11845del and
c.11693_11697dup seem to be associated with the more
severe clinical course of the disease resulting in ESRD
(End Stage Renal Disease) in the range from 44 to 48 years
(Table 3). Missense mutation in PKD1  c.8522G>A
p.E2771K seems to be associated either with milder or
more severe clinical course in the family 25. Patient 91
reached ESRD early at the age of 43 while patient 89 is
showing first signs of insufficiency at the age of 65. Non-
sense mutation in PKD2 c.916C>T p.R306X seems to be
connected to the milder clinical course (slow progress
towards ESRD) as already reported by Bulgarian and
Czech studies [40-42]. Comparisson to the clinical data of
the three Czech patients with age range of 51–81 years
(data not shown in the Table 3) reveiled that mutation
seems to be associated with cysts in liver.
Conclusion
In our study group of ADPKD patients six mutations and
eight polymorphisms were detected in PKD1  and one
mutation and three polymorphisms were detected in
PKD2. Three mutations have been described previously in
British, French, Czech and Bulgarian populations. Four
out of 7 mutations are novel and probably private. Three
newly described framesfift mutations in PKD1 seem to be
associated with more severe clinical course of the disease
resulting in ESRD (End Stage Renal Disease) in the age
range of 44 to 48 years. Nonsense mutation in PKD2
seems to be associated with cysts in liver and slower pro-
gression towards ESRD.
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